Physician profile
Pavan Sachan
NPI 1417906678
$4,867.05
in general payments reported to CMS, 2019-2025
41 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $779 · 2021: $1,152 · 2022: $873 · 2023: $706 · 2024: $605 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.16 | 2019-2025 | Rinvoq, Creon, Linzess |
| Amarin Pharma, INC. | $572.41 | 2019-2021 | |
| Daiichi Sankyo INC. | $326.54 | 2019-2023 | Injectafer |
| Amgen INC. | $316.46 | 2020-2023 | Repatha |
| Ardelyx, INC. | $273.94 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.36 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Pharmaceuticals, INC | $210.20 | 2019-2023 | Xarelto |
| Nestle Healthcare Nutrition INC. | $201.20 | 2021-2023 | |
| Pfizer INC. | $198.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $167.30 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $115.80 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $97.11 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $91.89 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $87.72 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.95 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Sachan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.